16.36
-0.24 (-1.45%)
| Previous Close | 16.60 |
| Open | 16.50 |
| Volume | 507,737 |
| Avg. Volume (3M) | 793,034 |
| Market Cap | 1,489,335,936 |
| Price / Earnings (Forward) | 140.85 |
| Price / Sales | 1.43 |
| Price / Book | 1.64 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -14.09% |
| Operating Margin (TTM) | -8.35% |
| Diluted EPS (TTM) | -1.28 |
| Quarterly Revenue Growth (YOY) | 11.20% |
| Total Debt/Equity (MRQ) | 19.56% |
| Current Ratio (MRQ) | 1.90 |
| Operating Cash Flow (TTM) | -70.00 M |
| Levered Free Cash Flow (TTM) | -52.90 M |
| Return on Assets (TTM) | -5.35% |
| Return on Equity (TTM) | -16.40% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Myriad Genetics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | -3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.60 |
|
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 2.01% |
| % Held by Institutions | 102.30% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (Piper Sandler, 46.70%) | Hold |
| Median | 21.00 (28.36%) | |
| Low | 13.00 (B of A Securities, -20.54%) | Sell |
| Average | 19.40 (18.58%) | |
| Total | 4 Hold, 1 Sell | |
| Avg. Price @ Call | 15.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 13 Dec 2024 | 13.00 (-20.54%) | Sell | 14.43 |
| UBS | 10 Dec 2024 | 18.00 (10.02%) | Hold | 15.34 |
| Leerink Partners | 09 Dec 2024 | 21.00 (28.36%) | Hold | 14.88 |
| Morgan Stanley | 18 Nov 2024 | 21.00 (28.36%) | Hold | 15.22 |
| Piper Sandler | 11 Nov 2024 | 24.00 (46.70%) | Hold | 17.31 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DAVIS MARK STEVEN | 15.34 | - | 22,816 | 349,997 |
| RAHA SAMRAAT S. | - | 14.51 | -29,578 | -429,177 |
| Aggregate Net Quantity | -6,762 | |||
| Aggregate Net Value ($) | -79,179 | |||
| Aggregate Avg. Buy ($) | 15.34 | |||
| Aggregate Avg. Sell ($) | 14.51 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RAHA SAMRAAT S. | Officer | 11 Dec 2024 | Disposed (-) | 29,578 | 14.51 | 429,177 |
| DAVIS MARK STEVEN | Director | 10 Dec 2024 | Acquired (+) | 22,816 | 15.34 | 349,997 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |